Anti-influenza virus probiotic agent and application thereof

The specific strains in probiotics regulate the intestinal flora and improve the immune response of influenza virus-infected mice, which solves the problems of poor influenza vaccine effect and obvious side effects of traditional treatment, and achieves effective prevention and relief of influenza virus.

CN118995468APending Publication Date: 2024-11-22SINOPHARM XINGSHA PHARM XIAMEN CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410827415.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-25
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The preventive effect of existing influenza vaccines is poor or ineffective due to the strong variability of influenza viruses, and traditional treatment methods have obvious side effects.

Method used

Probiotics including Lactobacillus rhamnosus, Lactobacillus reuteri and Lactobacillus casei are used to regulate the immune system through intestinal microbiota and increase resistance to influenza viruses. Strength, prepare medicines and health care products to prevent or treat influenza.

Benefits of technology

It significantly alleviates weight loss, lung damage and inflammation caused by influenza virus infection, reduces viral load and inflammatory factor levels, enhances antiviral gene expression, regulates the proportion of immune cells, and improves the immune response of influenza virus-infected mice.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004910916900000011
    Figure HDA0004910916900000011
  • Figure HDA0004910916900000012
    Figure HDA0004910916900000012
  • Figure HDA0004910916900000021
    Figure HDA0004910916900000021
Patent Text Reader

Abstract

The invention discloses an anti-influenza virus probiotic agent and application thereof. The probiotic agent provided by the invention comprises lactobacillus rhamnosus (Lactobacillus rhamnosus) CCFM1279, lactobacillus reuteri (Lactobacillus reuteri) CCFM1145 and lactobacillus casei (L.casei) CCFM1127, and has the effects of improving the innate immune response of a mouse infected with the influenza virus and further preventing and / or relieving the influenza virus infection. The probiotic agent disclosed by the invention can be used for preparing products (such as food, medicines or health-care food) for preventing and / or relieving influenza virus infection, and has a huge application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and in particular relates to an anti-influenza virus probiotic agent and application thereof. Background Art

[0002] Flu is the abbreviation of influenza. Unlike the common cold, the pathogen of flu is influenza virus. Influenza virus belongs to the influenza virus genus of the Orthomyxoviridae family. There are three common types: A, B, and C. Influenza A virus can infect multiple hosts, including mammals such as humans, pigs, poultry, and whales. The clinical manifestations of human influenza virus infection are usually manifested as fever, cough, muscle and joint pain, fatigue and other symptoms. Respiratory tract infections caused by influenza viruses can often spread from the upper respiratory tract to the lower respiratory tract, and the final pathological manifestation is primary influenza pneumonia. It should be noted that although the clinical manifestations of influenza virus infection are similar to those of the common cold, the condition is usually more serious. Some patients may develop serious complications such as pneumonia and other respiratory infections. Influenza viruses may also cause systemic inflammatory responses, leading to organ damage and multiple organ failure.

[0003] After the 20th century, influenza outbreaks and epidemics occurred from time to time, causing a large number of infections and deaths worldwide. These influenza epidemics have caused a large number of infections and deaths worldwide. At present, the main means of preventing and treating influenza are vaccination and drug treatment. Every year, the World Health Organization (WHO) predicts the influenza virus subtypes that are prevalent in that year to develop corresponding seasonal influenza vaccines. After the influenza vaccine is successfully vaccinated, the body produces specific immunity, which enables it to quickly identify and eliminate influenza viruses when infected, effectively preventing the occurrence of influenza or reducing its severity. Since the vaccine for preventing influenza relies on the immune memory function of the body's adaptive immunity, it has strong specificity. It often causes the influenza vaccine to be ineffective or ineffective against highly variable influenza viruses, which has certain defects.

[0004] In recent years, with the progress of the study of the "lung-gut axis", there is a clear correlation between intestinal microecology and lung diseases. The lung-gut axis refers to the interconnected physiological and pathological processes between the intestines and the respiratory tract. It refers to the interaction between the intestines and the lungs through the immune system, microbial communities and other physiological pathways, that is, the mutual influence between the intestines and the lungs. As a microbial community in the intestine, the intestinal flora is believed to play an important role in maintaining the body's immune homeostasis. More and more evidence shows that the intestinal flora is closely related to respiratory health, and an imbalance in the intestinal flora may increase the risk of respiratory diseases such as influenza through the immune system. Studies have found that specific probiotics can affect the regulation of the immune system through the intestinal flora, thereby affecting the immune response of the respiratory tract or increasing the protection rate of vaccines to protect the body from influenza viruses.

[0005] Therefore, perhaps we can start with intestinal microorganisms and try to find new drugs or new methods to prevent and treat influenza, so as to overcome the shortcomings of existing therapeutic drugs and treatments, such as obvious side effects. Summary of the invention

[0006] The first object of the present invention is to provide an anti-influenza virus probiotic, which comprises a Lactobacillus rhamnosus CCFM1279 strain with a preservation number of GDMCC No.64726, a Lactobacillus reuteri CCFM1145 strain with a preservation number of GDMCC No.60459, and a Lactobacillus casei CCFM1127 strain with a preservation number of GDMCC No.61021; the ratio of the number of live bacteria of the CCFM1279 strain, the CCFM1145 strain and the CCFM1127 strain is 1:(0.1-10):(0.1-10);

[0007] The Lactobacillus rhamnosus CCFM1279 strain was deposited in the Guangdong Provincial Microbiological Culture Collection Center on June 12, 2024, with the collection number GDMCC No. 64726, and the collection address is 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.

[0008] The Lactobacillus reuteri CCFM1145 strain is disclosed in patent application CN112322527A and was deposited in Guangdong Provincial Microbiological Culture Collection Center on August 19, 2020, with the deposit number GDMCC No.61151, and the deposit address is 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.

[0009] The Lactobacillus casei CCFM1127 strain is disclosed in patent application CN111560338A and has been deposited in Guangdong Provincial Microbiological Culture Collection Center on May 6, 2020, with a deposit number of GDMCC No.61021, and the deposit address is 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.

[0010] Preferably, in the probiotic agent, the total number of viable bacteria is not less than 1×10 6 CFU / mL.

[0011] Preferably, the dosage form of the probiotic includes lyophilized powder, capsule, tablet or granule.

[0012] The second object of the present invention is to provide the use of the above-mentioned anti-influenza virus probiotics in the preparation of drugs for preventing or treating influenza virus infection.

[0013] The third object of the present invention is to provide the use of the above-mentioned anti-influenza virus probiotics in the preparation of food or health products for preventing or alleviating the symptoms of influenza virus infection.

[0014] The fourth object of the present invention is to provide the use of the above-mentioned anti-influenza virus probiotic in the preparation of a product having at least one of the following functions:

[0015] (1) Alleviate weight loss in mice infected with influenza virus;

[0016] (2) Reduce lung damage in mice infected with influenza virus;

[0017] (3) Inflammatory infiltration in the lungs of mice infected with influenza virus was reduced;

[0018] (4) Down-regulate the viral load in the lungs of mice infected with influenza virus;

[0019] (5) downregulate IL-6 levels in the serum of mice infected with influenza virus;

[0020] (6) downregulate TNF-α levels in the serum of mice infected with influenza virus;

[0021] (7) downregulate IL-1β levels in the serum of mice infected with influenza virus;

[0022] (8) Upregulates the expression level of the antiviral gene OAS1 in the lungs of mice infected with influenza virus;

[0023] (9) Down-regulate the percentage of monocytes in the blood of mice infected with influenza virus;

[0024] (10) Down-regulate the percentage of neutrophils in the blood of mice infected with influenza virus.

[0025] Compared with the prior art, the present invention has the following beneficial effects:

[0026] The present invention provides a probiotic agent capable of improving the innate immune response of mice infected with influenza virus, thereby preventing and / or alleviating influenza virus infection, which is specifically embodied in:

[0027] 1. Alleviate weight loss in mice infected with influenza virus;

[0028] 2. Reduce lung damage in mice infected with influenza virus;

[0029] 3. Inflammatory infiltration in the lungs of mice infected with influenza virus was reduced;

[0030] 4. Down-regulate the viral load in the lungs of mice infected with influenza virus;

[0031] 5. Down-regulate IL-6 levels in the serum of mice infected with influenza virus;

[0032] 6. Down-regulate TNF-α levels in the serum of mice infected with influenza virus;

[0033] 7. Down-regulate IL-1β levels in the serum of mice infected with influenza virus;

[0034] 8. Upregulate the expression level of the antiviral gene OAS1 in the lungs of mice infected with influenza virus;

[0035] 9. Down-regulate the percentage of monocytes in the blood of mice infected with influenza virus;

[0036] 10. Down-regulate the percentage of neutrophils in the blood of mice infected with influenza virus.

[0037] Therefore, the probiotics of the present invention have great application prospects in the preparation of products (such as food, medicine or health food, etc.) for preventing and / or alleviating influenza virus infection. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] The present invention will be further described below in conjunction with embodiments with reference to the accompanying drawings.

[0039] Figure 1 This is a comparison chart of weight changes in different groups of influenza mice.

[0040] Figure 2 This is a comparison of L-lactate dehydrogenase levels in the bronchoalveolar lavage fluid of different groups of influenza mice.

[0041] Figure 3 Comparison of lung tissue pathology sections of influenza mice in different groups.

[0042] Figure 4 A comparison of the lung viral loads of different groups of influenza mice.

[0043] Figure 5 This is a comparison chart of serum IL-6 levels in different groups of influenza mice.

[0044] Figure 6 This is a comparison chart of serum TNF-α levels in different groups of influenza mice.

[0045] Figure 7 This is a comparison of serum IL-1β levels in different groups of influenza mice.

[0046] Figure 8 This is a comparison of the expression levels of the antiviral gene OAS1 in the lungs of different groups of influenza mice.

[0047] Fig. 9 The figure shows a comparison of the blood monocyte percentages of influenza mice in different groups.

[0048] Fig.10 The figure shows a comparison of the blood neutrophil percentages of influenza mice in different groups. DETAILED DESCRIPTION

[0049] In order to better understand the present invention, the present invention is further described in detail below in conjunction with the embodiments and drawings. However, those skilled in the art understand that the following embodiments are not limitations on the scope of protection of the present invention, and any changes and modifications made on the basis of the present invention are within the scope of protection of the present invention.

[0050] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0051] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0052] The SPF-grade ICR female mice involved in the following examples were purchased from Beijing Weitonglihua.

[0053] The culture medium involved in the following examples is as follows:

[0054] MRS medium formula (1L): peptone 10g, beef extract 10g, yeast powder 5g, glucose 20g, K 2 HPO 4 2g, diammonium citrate 2g, sodium acetate 2g, Tween 80 1mL, MgSO 4 7H 2 O0.5g, MnSO 4 ·4H 2 O0.25g, pH is 7.2-7.4.

[0055] MRS solid medium formula (1L): peptone 10g, beef extract 10g, yeast powder 5g, glucose 20g, K 2 HPO 4 2g, diammonium citrate 2g, sodium acetate 2g, Tween 80 1mL, MgSO 4 7H 2 O0.5g, MnSO 4 ·4H 2 O0.25g, agar 20g, pH 7.2-7.4.

[0056] The detection methods involved in the following embodiments are as follows:

[0057] Method for detecting the number of viable bacteria: adopt the national standard "GB4789.35-2016 National Food Safety Standard Food Microbiology Detection Lactic Acid Bacteria Detection".

[0058] Acidity detection method: adopt national standard GB431334-2010.

[0059] Lactobacillus rhamnosus CCFM1279, Lactobacillus reuteri CCFM1145 and Lactobacillus casei CCFM1127 are strains isolated from different fecal samples using the same method.

[0060] Example 1 Cultivation of strains and preparation of bacterial suspension

[0061] Lactobacillus rhamnosus CCFM1279, Lactobacillus reuteri CCFM1145 and Lactobacillus casei CCFM1127 were inoculated into MRS solid culture medium and cultured at 37°C for 24 hours. Their colonies were observed and their bacteria were observed under a microscope. It was found that their colonies were milky white, round and smooth, and their bacteria were slightly irregular in shape with rounded ends. They were Campylobacter, usually present alone, in pairs and in small clusters.

[0062] Lactobacillus rhamnosus CCFM1279, Lactobacillus reuteri CCFM1145 and Lactobacillus casei CCFM1127 were respectively inoculated into MRS liquid culture medium and cultured at 37°C for 24 h, then transferred to fresh MRS liquid culture medium and cultured under the same conditions for 12 h, the bacteria were centrifuged at 8000×g for 15 min, the bacteria were washed with 0.9% saline and centrifuged again at 8000×g for 10 min, the supernatant was discarded and the bacteria were collected, resuspended with 30% (m / v) sucrose solution, and frozen at -80°C for use.

[0063] When the composite probiotics composed of Lactobacillus rhamnosus CCFM1279, Lactobacillus reuteri CCFM1145 and Lactobacillus casei CCFM1127 are used for oral administration to mice in a ratio of 1:1:1, the mixture is taken out from -80°C and centrifuged to discard the supernatant, and oligofructose, oligoxylose, elderberry juice powder, composite berry powder, honeysuckle pollen, dandelion powder, resistant dextrin, lactitol, micronized xylitol, rice flour, linseed diglyceride edible oil powder are added, and the mixture is resuspended with sterile physiological saline to obtain a bacterial suspension for oral administration. The ratio of Lactobacillus rhamnosus CCFM1279, Lactobacillus reuteri CCFM1145 and Lactobacillus casei CCFM1127 in the composite bacterial agent can be any ratio within the range of 1:(0.1-10):(0.1-10).

[0064] Example 2 Effect of probiotics on alleviating weight loss in mice infected with H1N1 influenza virus

[0065] The 3-4 week old SPF grade ICR female mice were divided into 4 groups, namely blank control group (Control), influenza model group (Model), oseltamivir drug treatment group (Treatment) and compound probiotic formula experimental group (Mix), 10 mice in each group, all groups were free to drink water and eat. The animals were raised in the Experimental Animal Center of Yangzhou University, fed with ordinary feed, with a constant temperature of 21-26℃, humidity of 40-70%, noise less than or equal to 60dB, and animal illumination of 15-20LX (all animal experimental procedures were reviewed and approved by the Animal Welfare and Ethics Management Committee of Yangzhou University).

[0066] The experimental period lasted for 22 days. After the mice underwent a 10-day adaptation period, starting from the 11th day, the compound probiotic formula experimental group was gavaged with 0.2 mL of compound probiotic formula suspension with a mass of 0.35 g per day, and the blank control group, influenza model group, and oseltamivir drug treatment group were gavaged with the same amount of sterile saline per day.

[0067] On the 17th day, the mice were challenged with 10 μL of 5LD 50 The mice were infected with nasal drops of H1N1 virus suspension to complete the modeling. The oseltamivir drug treatment group needed to be gavaged with oseltamivir within 1 hour after modeling. After the modeling was completed, gavage continued every day. The composite probiotic formula experimental group was gavaged with 0.2 mL of composite probiotic formula suspension with a mass of 0.35 g every day. The blank control group, influenza model group, and oseltamivir drug treatment group were gavaged with the same amount of sterile saline every day until the mice were sacrificed on the 22nd day.

[0068] After the model was established on the 17th day, the mice were weighed after oral administration every day, and the weight changes were recorded for five consecutive days until the mice were sacrificed on the 22nd day. Figure 1 shown.

[0069] Depend on Figure 1 It can be seen that the weight of mice began to decrease on the third day after infection, and the weight loss was most obvious on the fifth day (P<0.05). Compared with the blank control group (Control), the weight loss of the influenza model group (Model) was more than 10%, the weight loss of the oseltamivir treatment group (Treatment) was about 0.23%, and the weight loss of the compound probiotic formula experimental group was only 3.88% (P<0.01).

[0070] This indicates that the composite probiotic formula of the present invention can significantly improve the weight loss symptoms of influenza mice.

[0071] Example 3 Effect of probiotics on the alleviation of lung damage in mice infected with H1N1 influenza virus

[0072] The mouse grouping and modeling methods were the same as in Example 2.

[0073] On day 22, the mice were sacrificed and bronchoalveolar lavage fluid was obtained.

[0074] Depend on Figure 2 It can be seen that the content of L-lactate dehydrogenase in the bronchoalveolar lavage fluid of mice in the normal group was low; while the content of L-lactate dehydrogenase in the bronchoalveolar lavage fluid of mice in the model group increased significantly, indicating that H1N1 influenza virus infection caused damage to the lungs of mice and led to infiltration of lung tissue fluid; and the content of L-lactate dehydrogenase in the bronchoalveolar lavage fluid of mice in the composite probiotic formula experimental group was significantly reduced by 65.13% (P<0.001) compared with the influenza model group.

[0075] The above experimental results show that the compound probiotic formula can alleviate lung damage caused by H1N1 influenza virus infection, and its effect is significantly better than oseltamivir.

[0076] Example 4 Effect of probiotics on the alleviation of lung inflammation in mice infected with H1N1 influenza virus

[0077] The mouse grouping and modeling methods were the same as in Example 2.

[0078] The mice were killed on the 22nd day, and the left lung lobe of the mice was taken for pathological sectioning and histopathological analysis. Figure 3 .

[0079] Depend on Figure 3 It can be seen that after H1N1 influenza virus infection, the lungs of the influenza model group mice showed severe inflammatory infiltration and hemorrhage, while the blank control group mice had no inflammatory cell infiltration around the bronchi and blood vessels in the lungs, the alveolar structure was intact, and there was no hemorrhage or inflammatory cell aggregation. The lung inflammation of the mice in the compound probiotic formula experimental group was significantly alleviated, the infiltration of inflammatory cells around the blood vessels was reduced, the alveolar morphology was intact, and there was no obvious bleeding.

[0080] The above experimental results show that the compound probiotic formula can improve the pulmonary inflammatory infiltration in mice infected with H1N1 influenza virus.

[0081] Example 5 Effect of probiotics on lung viral load in mice infected with H1N1 influenza virus

[0082] The mouse grouping and modeling methods were the same as in Example 2.

[0083] The mice were killed on day 22 to obtain lung tissue. The results of qPCR detection of lung tissue viral load after RNA extraction are shown in Figure 4 .

[0084] Table 1 qPCR detection primers

[0085] qPCR detection primers sequence NP_F GGCACCAAACGGTCTTACGA (as shown in SEQ ID NO: 1) NP_R TCACCTGATCAACTCCATTACCA (as shown in SEQ ID NO: 2)

[0086] Depend on Figure 4 It can be seen that the lung viral load of mice in the compound probiotic formula experimental group was significantly reduced by 75% compared with that of mice in the influenza model group (P < 0.0001).

[0087] The above results show that the compound probiotic formula experimental group can significantly reduce the viral load in the lungs of mice.

[0088] Example 6 Effect of probiotics on serum inflammatory factor IL-6 levels in mice infected with H1N1 influenza virus

[0089] The mouse grouping and modeling methods were the same as in Example 2.

[0090] On the 22nd day, the mice were killed, the blood was centrifuged to obtain the supernatant, and the IL-6 level in the serum was detected using an ELISA kit.

[0091] Depend on Figure 5 It can be seen that the IL-6 level in the serum of mice in the influenza model group was significantly increased compared with the blank control group; while the IL-6 level in the serum of mice in the composite probiotic formula experimental group was reduced by 48.2% (P < 0.05) compared with the influenza model group.

[0092] The above experimental results show that oral administration of the compound probiotic formula can effectively reduce the level of inflammatory factor IL-6 in the serum of mice infected with influenza virus, and further alleviate the inflammatory response caused by influenza virus.

[0093] Example 7 Effect of probiotics on serum inflammatory factor TNF-α levels in mice infected with H1N1 influenza virus

[0094] The mouse grouping and modeling methods were the same as in Example 2.

[0095] On the 22nd day, the mice were killed, the blood was centrifuged to obtain the supernatant, and the TNF-α level in the serum was detected using an ELISA kit.

[0096] Depend on Figure 6 It can be seen that the TNF-α level in the serum of mice in the influenza model group was significantly increased compared with the blank control group; while the TNF-α level in the serum of mice in the composite probiotic formula experimental group was significantly reduced by 50.8% (P<0.05) compared with the influenza model group.

[0097] The above experimental results show that oral administration of the compound probiotic formula can effectively reduce the level of inflammatory factor TNF-α in the serum of mice infected with influenza virus, and further alleviate the inflammatory response caused by influenza virus.

[0098] Example 8 Effect of probiotics on serum inflammatory factor IL-1β levels in mice infected with H1N1 influenza virus

[0099] The mouse grouping and modeling methods were the same as in Example 2.

[0100] On the 22nd day, the mice were killed, the blood was centrifuged to obtain the supernatant, and the IL-1β level in the serum was detected using an ELISA kit.

[0101] Depend on Figure 7 It can be seen that the IL-1β level in the serum of mice in the blank control group was reduced by 57.1% (P=0.115) compared with the influenza model group; while the IL-1β level in the serum of mice in the composite probiotic formula experimental group was reduced by 38.2% (P=0.282) compared with the influenza model group.

[0102] The above experimental results show that oral administration of the compound probiotic formula can effectively reduce the level of inflammatory factor IL-1β in the serum of mice infected with influenza virus, and further alleviate the inflammatory response caused by influenza virus.

[0103] Example 9 Effect of probiotics on the expression of antiviral gene OAS1 in the lungs of mice infected with H1N1 influenza virus

[0104] The mouse grouping and modeling methods were the same as in Example 2.

[0105] The mice were killed on day 22 to obtain lung tissue. After RNA extraction, qPCR was used to detect the expression of the antiviral gene OAS1 in lung tissue. Figure 8 .

[0106] Table 1 qPCR detection primers

[0107] qPCR detection primers sequence OAS1_F GAAGAGGCTGATGTGTGGCT (as shown in SEQ ID NO: 3) OAS1_R TGTCCAGTTCTCTTCTACCTGC (as shown in SEQ ID NO: 4)

[0108] Depend on Figure 8 It can be seen that the expression of the antiviral gene OAS1 in the lung tissue of mice in the compound probiotic formula experimental group was significantly increased by 941.9% (P < 0.01) compared with that in the influenza model group.

[0109] The above results show that the compound probiotic formula experimental group can significantly enhance the expression of the antiviral gene OAS1 in the lung tissue of mice.

[0110] Example 10 Effect of probiotics on blood monocytes of mice infected with H1N1 influenza virus

[0111] The mouse grouping and modeling methods were the same as in Example 2.

[0112] The mice were killed on the 22nd day, and the blood was placed in an anticoagulant tube and gently shaken to allow the blood to fully contact the anticoagulant. The blood was then sent to an animal hospital for routine blood analysis (in the early stages of influenza virus infection, a large number of natural immune cells, such as neutrophils and monocytes, will participate in the defense process).

[0113] Depend on Fig. 9 It can be seen that after mice suffer from influenza, the proportion of natural immune cells in their bodies will undergo different changes. The level of monocytes in the mice of the influenza model group (Model) changed and was significantly higher than that of the blank control group (Control) (P<0.05), while the various indicators of the mice in the compound probiotic formula experimental group tended to normal values, with no significant difference from the blank control group (Control). Among them, compared with the influenza model group, the percentage of blood monocytes in the mice in the compound probiotic formula experimental group decreased by 19.1% (P=0.24).

[0114] This indicates that the compound probiotic formula ingested by mice can participate in the body's immune regulation, reduce the percentage of monocytes in the blood, help the body resist the invasion of influenza virus, and maintain the body's health.

[0115] Example 11 Effect of probiotics on blood neutrophils in mice infected with H1N1 influenza virus The mouse grouping and modeling methods were the same as in Example 2.

[0116] The mice were killed on the 22nd day, and the blood was placed in an anticoagulant tube and gently shaken to allow the blood to fully contact the anticoagulant. The blood was then sent to an animal hospital for routine blood analysis (in the early stages of influenza virus infection, a large number of natural immune cells, such as neutrophils and monocytes, will participate in the defense process).

[0117] Depend on Fig.10 It can be seen that after mice suffer from influenza cold, the proportion of natural immune cells in their bodies will undergo different changes. The level of neutrophils in the mice of the influenza model group (Model) changed and was significantly higher than that of the blank control group (Control) (P<0.05), while the various indicators of the mice in the compound probiotic formula experimental group tended to normal values, with no significant difference from the blank control group (Control). Among them, compared with the influenza model group, the percentage of neutrophils in the blood of mice in the compound probiotic formula experimental group decreased by 12.4% (P=0.359).

[0118] This indicates that the compound probiotic formula ingested by mice can participate in the body's immune regulation, reduce the percentage of neutrophils in the blood, help the body resist the invasion of influenza virus, and maintain the body's health.

[0119] Example 12 Preparation of probiotic powder

[0120] The seed liquid of Lactobacillus rhamnosus CCFM1279, Lactobacillus reuteri CCFM1145 and Lactobacillus casei CCFM1127 preserved in the bacterium preservation tube was inoculated into MRS medium at an inoculum amount of 3% of the total mass of the culture medium, and cultured at 37°C for 12 hours to obtain a culture solution; the culture solution was centrifuged to collect the bacteria; the bacteria were washed three times with a phosphate buffer with a pH of 7.2, and then resuspended with a trehalose freeze-drying protective agent with a trehalose concentration of 100 g / L, and the mass ratio of the freeze-drying protective agent to the bacteria was controlled to be 2:1 to obtain a resuspension; the resuspension was precooled at -80°C for 1.5 hours and then immediately transferred to a freeze dryer for drying for 24 hours to obtain bacterial powders of Lactobacillus rhamnosus CCFM1279, Lactobacillus reuteri CCFM1145 and Lactobacillus casei CCFM1127, and the powders were prepared according to the method of Lactobacillus rhamnosus CCFM1279 (4*10 11 CFU / g) 3.9%, Lactobacillus reuteri CCFM1145 (2*10 11 CFU / g) 3%, Lactobacillus casei CCFM1127 (5*10 11 The composite probiotic formula powder is prepared by calculating the weight percentage of 0.4% (CFU / g), 10% (fructooligosaccharide), 4% (xylo-oligosaccharide), 5% (elderberry juice powder), 28% (compound berry powder), 0.1% (honeysuckle pollen), 0.1% (dandelion powder), 25% (resistant dextrin), 7.5% (lactitol), 6% (micro-powder xylitol), 2.8% (rice flour), and 5% (flaxseed diglyceride edible oil powder).

[0121] In summary, the probiotics of the present invention have the effect of improving the innate immune response of mice infected with influenza virus, thereby preventing and / or alleviating influenza virus infection. The probiotics of the present invention can be used to prepare products (such as food, medicine or health food, etc.) that prevent and / or alleviate influenza virus infection, and have great application prospects.

[0122] Although the specific implementation modes of the present invention are described above, those skilled in the art should understand that the specific implementation modes described are only illustrative and are not intended to limit the scope of the present invention. Equivalent modifications and changes made by those skilled in the art in accordance with the spirit of the present invention should be included in the scope of protection of the claims of the present invention.

Claims

1. A probiotic for resisting influenza virus, characterized in that: The anti-influenza virus probiotic comprises a Lactobacillus rhamnosus CCFM1279 strain with a preservation number of GDMCC No. 64726, a Lactobacillus reuteri CCFM1145 strain with a preservation number of GDMCC No. 61151, and a Lactobacillus casei CCFM1127 strain with a preservation number of GDMCC No. 61021; the ratio of the number of live bacteria of the CCFM1279 strain, the CCFM1145 strain and the CCFM1127 strain is 1:(0.1-10):(0.1-10).

2. The anti-influenza virus probiotic according to claim 1, characterized in that: In the probiotic, the ratio of the number of live bacteria of CCFM1279 strain, CCFM1145 strain and CCFM1127 strain is 1:1:1 and the total number of live bacteria is not less than 1×10 6 CFU / mL.

3. The anti-influenza virus probiotic according to claim 1, characterized in that: The dosage form of the probiotics includes freeze-dried powder, capsules, tablets or granules.

4. Use of the anti-influenza virus probiotic according to any one of claims 1 to 3 in the preparation of a medicament for preventing or treating influenza virus infection.

5. Use of the anti-influenza virus probiotic according to any one of claims 1 to 3 in the preparation of food or health products for preventing or alleviating symptoms of influenza virus infection.

6. Use of the anti-influenza virus probiotic according to any one of claims 1 to 3 in the preparation of a product having at least one of the following functions: (1) Alleviate weight loss in mice infected with influenza virus; (2) Reduce lung damage in mice infected with influenza virus; (3) Inflammatory infiltration in the lungs of mice infected with influenza virus was reduced; (4) Down-regulate the viral load in the lungs of mice infected with influenza virus; (5) downregulate IL-6 levels in the serum of mice infected with influenza virus; (6) downregulate TNF-α levels in the serum of mice infected with influenza virus; (7) downregulate IL-1β levels in the serum of mice infected with influenza virus; (8) Upregulates the expression level of the antiviral gene OAS1 in the lungs of mice infected with influenza virus; (9) Down-regulate the percentage of monocytes in the blood of mice infected with influenza virus; (10) Down-regulate the percentage of neutrophils in the blood of mice infected with influenza virus.